ARQT News and Press, Arcutis Biotherapeutics Inc. From 12/09/20

Broad and deep portfolio of highly differentiated product candidates aligned with needs of patients and doctors Robust pipeline includes 4 development programs addressing 7 dermatological diseases, including 3 programs in Phase 2 or Phase 3 for 5 different indications Pipeline has...

Phase 3 trials’ topline data anticipated in the first quarter of 2021 and potential New Drug Application (NDA) submission anticipated by the end of 2021 Roflumilast cream potential “Best in Class” topical PDE4 inhibitor Plaque psoriasis affects approximately 8...

WESTLAKE VILLAGE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-der...

Once-daily roflumilast cream demonstrated favorable safety and tolerability over 52 to 64 weeks of treatment At 52 to 64 weeks of treatment, over one-third of subjects demonstrated IGA Success and 45% of subjects had attained an IGA of clear or almost clear Data further support th...

Arcutis Biotherapeutics (ARQT) surges 17% premarket in reaction to positive top line data from its Phase 2b clinical trial evaluating ARQ-154 (topical roflumilast foam) as a potential treatment for scalp psoriasis. Roflumilast foam 0.3% administered once daily for 8 weeks demon...

Roflumilast foam demonstrated statistically significant improvement on the trial’s primary and multiple secondary endpoints Once-daily roflumilast foam demonstrated a favorable safety and tolerability profile Roflumilast foam potential “Best in Class” topical ...

WESTLAKE VILLAGE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-der...

Evelo Biosciences seeks to harass the ability of microbes in the gut to direct the immune system. The approach is novel and unproven and thus investing is a very high risk proposition. If efficacious, these are benign, inexpensive to manufacture products which can provide treatmen...

Arcutis Biotherapeutics (ARQT): Q3 GAAP EPS of -$1.01 misses by $0.10.Cash, cash equivalents and marketable securities of $189.7MShares -1.07% AH.Press Release For further details see: Arcutis Biotherapeutics EPS misses by $0.10

Pivotal Phase 3 data in plaque psoriasis anticipated in first quarter of 2021 Pivotal Phase 3 trials in atopic dermatitis anticipated to begin in late 2020 or early 2021 Recent positive Phase 2 data in seborrheic dermatitis supports pipeline advancement in indication that impacts ...